USG Joint Compound

Product Description

United States Gypsum Company (USG) manufactured joint compound under its own brand from approximately 1937 through 1976. Joint compound — also widely referred to as “drywall mud” or “taping compound” — is a paste-like material applied over gypsum wallboard seams, nail dimples, corners, and surface imperfections during interior construction finishing. Once applied, the compound is allowed to dry and then sanded smooth before painting or texturing.

USG was among the most prominent manufacturers in the American building materials industry during the twentieth century, and its joint compound products were distributed nationally through lumber yards, hardware retailers, and wholesale building supply networks. The compound was used extensively in residential, commercial, and institutional construction projects throughout the mid-century building boom, making it a ubiquitous presence on job sites across the United States during the decades it contained asbestos.

Joint compound was applied in multiple successive coats — typically a base coat, a finishing coat, and sometimes additional skim coats — meaning tradespeople who worked with the product were exposed to it repeatedly over the course of individual projects and across entire careers.

Asbestos Content

USG joint compound manufactured during the relevant production period contained chrysotile asbestos as a formulation ingredient. Chrysotile, also known as white asbestos, is a serpentine-form mineral fiber that was incorporated into joint compound and similar finishing products for several functional reasons: it improved the workability and spreadability of the wet compound, helped control cracking during the drying process, and contributed to the overall structural integrity of the dried material.

Chrysotile asbestos was the predominant fiber type used commercially in the United States and was added during the mixing stage of compound production. Its inclusion in joint compound was consistent with broader industry practices during the mid-twentieth century, when asbestos was routinely incorporated into construction materials for its physical properties without adequate acknowledgment of the associated health hazards.

The asbestos content of USG joint compound products was reduced and ultimately eliminated over the course of the 1970s as regulatory pressure intensified and awareness of asbestos-related disease grew. The Environmental Protection Agency, the Occupational Safety and Health Administration (OSHA), and the Consumer Product Safety Commission each took steps during this period to restrict or eliminate asbestos in consumer and construction products. USG had phased asbestos out of its joint compound formulations by 1976.

How Workers Were Exposed

Workers who mixed, applied, or sanded USG joint compound during the product’s asbestos-containing years faced potential inhalation exposure to chrysotile asbestos fibers. The nature of joint compound work meant that exposure was not incidental — it was built into the ordinary performance of the job.

Mixing dry or semi-dry compound generated airborne dust that could contain asbestos fibers. Workers who opened bags of powdered compound or mixed bulk product in buckets or mechanical mixers were exposed at this stage.

Application involved spreading and feathering the compound across large surface areas using hand tools, which could disturb settled dust and re-suspend fibers.

Sanding was the most hazardous phase of joint compound work. Once dried, the compound had to be abraded smooth before finishing. Dry sanding — the most common method during the relevant period — generates fine, respirable dust. Because chrysotile fibers are microscopic and remain suspended in air for extended periods, workers in enclosed or poorly ventilated spaces could inhale significant quantities during sanding operations.

Beyond those who worked directly with joint compound, others present on the same job sites — including carpenters, painters, electricians, and general laborers — could also be exposed as bystanders when sanding operations were underway. Building occupants in spaces where renovation or repair work was occurring faced similar secondary exposure risks.

OSHA’s current permissible exposure limit (PEL) for asbestos is 0.1 fibers per cubic centimeter of air as an eight-hour time-weighted average. Studies and industrial hygiene records have documented that dry sanding of asbestos-containing joint compound could produce airborne fiber concentrations many times in excess of this threshold, even accounting for the lower regulatory limits in place during earlier decades.

Because joint compound was applied and finished on virtually every interior gypsum wallboard installation, the population of potentially exposed workers was large, spanning the residential construction trades, commercial interior contractors, and the industrial maintenance and renovation workforce. Exposure was ongoing throughout the product’s production years, and latency periods for asbestos-related disease mean that individuals exposed during the 1950s, 1960s, and early 1970s may only have received diagnoses in subsequent decades.

Documented Trust Fund / Legal Options

USG remains a solvent, operating company and has not established a bankruptcy trust fund for asbestos-related claims associated with its joint compound or other products. Accordingly, there is no dedicated asbestos trust through which individuals may file claims against USG for joint compound exposure.

Individuals diagnosed with asbestos-related diseases following exposure to USG joint compound may pursue civil litigation directly against the company. Litigation records document that plaintiffs have brought product liability claims against United States Gypsum alleging that the company’s joint compound contained asbestos and that exposure to the product caused or contributed to serious illness. Plaintiffs alleged that USG knew or should have known of the health hazards associated with chrysotile asbestos and failed to adequately warn workers and consumers of those risks.

Asbestos-related diseases that have formed the basis of litigation in this context include mesothelioma, asbestosis, lung cancer, and other asbestos-related conditions. Mesothelioma — a malignancy of the pleural or peritoneal lining — is considered a signature disease of asbestos exposure and carries a recognized association with chrysotile fiber inhalation.

Because many individuals were exposed to multiple asbestos-containing products over the course of their working lives, asbestos litigation often involves claims against several defendants simultaneously. In addition to any direct claim against USG, individuals exposed to joint compound may have viable claims through trust funds established by other manufacturers whose products were present on the same job sites — including manufacturers of asbestos-containing ceiling materials, floor products, insulation, or other construction goods. Identifying all potential sources of exposure is a critical step in pursuing compensation.

Statutes of limitations for asbestos claims vary by state and typically run from the date of diagnosis rather than the date of exposure, but timely consultation with an attorney experienced in asbestos litigation is essential.

Individuals who believe they were exposed to USG joint compound and have since received a diagnosis of mesothelioma or another asbestos-related illness should seek legal counsel to assess their options for civil recovery.